Table 3 Treatment-emergent adverse events attributable to G47Δ according to severity grade, n = 19
From: Intratumoral oncolytic herpes virus G47∆ for residual or recurrent glioblastoma: a phase 2 trial
Body system and adverse event, n (%) | Grade 1 | Grade 2 | Grade 3 | Grade 4 | Grade 5 |
|---|---|---|---|---|---|
Patient number with any adverse event | 2 (10.5) | 10 (52.6) | 5 (26.3) | 2 (10.5) | |
General disorder | |||||
Fever | 6 (31.6) | 10 (52.6) | 1 (5.3) | 0 (0) | 0 (0) |
Gastrointestinal disorder | |||||
Vomiting | 3 (15.8) | 7 (36.8) | 1 (5.3) | 0 (0) | 0 (0) |
Nausea | 5 (26.3) | 5 (26.3) | 0 (0) | 0 (0) | 0 (0) |
Nervous system disorder | |||||
Seizure | 0 (0) | 3 (15.8) | 0 (0) | 0 (0) | 0 (0) |
Cerebral edema | 2 (10.5) | 1 (5.3) | 0 (0) | 0 (0) | 0 (0) |
Neuropathy–sensory | 1 (5.3) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
Headache | 1 (5.3) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
Blood | |||||
Anemia | 1 (5.3) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
Investigations | |||||
Lymphocyte count decreased | 1 (5.3) | 3 (15.8) | 3 (15.8) | 2 (10.5) | 0 (0) |
White blood cell count decreased | 2 (10.5) | 3 (15.8) | 1 (5.3) | 0 (0) | 0 (0) |
Neutrophil count decreased | 0 (0) | 2 (10.5) | 1 (5.3) | 0 (0) | 0 (0) |
Platelet count decreased | 3 (15.8) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
Bilirubin increased | 1 (5.3) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
γ-Glutamyl transpeptidase increased | 1 (5.3) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
PT-INR increased | 1 (5.3) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
Hypoalbuminemia | 1 (5.3) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
Hyponatremia | 1 (5.3) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
